Wednesday, October 14, 2026

Less Than One Hour Before The Market Open, Virgin Galactic Is Up By 4%

ViaNews Editorial Team

November 14, 2023

Less Than One Hour Before The Market Open, Virgin Galactic Is Up By 4%

(VIANEWS) - The NYSE opens tomorrow, in less than one hours, and today's Virgin Galactic (NYSE: SPCE)'s post-market value is already 4.5% up.

Virgin Galactic's last close was $1.89, 71.41% below its 52-week high of $6.61.

The last session, NYSE ended with Virgin Galactic (SPCE) rising 5.59% to $1.89. NYSE jumped 0.1% to $15,403.14, after two sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session.

About Virgin Galactic

Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico.

Earnings Per Share

As for profitability, Virgin Galactic has a trailing twelve months EPS of $-1.81.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -90.56%.

Moving Average

Virgin Galactic's value is above its 50-day moving average of $1.78 and way under its 200-day moving average of $3.56.

Volume

Today's last reported volume for Virgin Galactic is 10308590 which is 54.66% below its average volume of 12226000.

More news about Virgin Galactic (SPCE).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com